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Abstract
Background: Tau protein exists as six different isoforms that differ by the inclusion or exclusion
of exons 2, 3 and 10. Exon 10 encodes a microtubule binding repeat, thereby resulting in three
isoforms with three microtubule binding repeats (3R) and three isoforms that have four
microtubule binding repeats (4R). In normal adult brain, the relative amounts of 3R tau and 4R tau
are approximately equal. These relative protein levels are preserved in Alzheimer's disease,
although in other neurodegenerative tauopathies such as progressive supranuclear palsy,
corticobasal degeneration and Pick's disease, the ratio of 3R:4R is frequently altered. Because tau
isoforms are not equally involved in these diseases, it is possible that they either have inherently
unique characteristics owing to their primary structures or that post-translational modification,
such as phosphorylation, differentially affects their properties.
Results: We have determined the effects of phosphorylation by a kinase widely believed to be
involved in neurodegenerative processes, glycogen synthase kinase-3β (GSK-3β), on the
microtubule binding and inducer-initiated polymerization of these isoforms in vitro. We have found
that each isoform has a unique microtubule binding and polymerization profile that is altered by
GSK-3β. GSK-3β phosphorylation had differential effects on the isoforms although there were
similarities between isoforms and the effects were generally mild.
Conclusion: These results indicate that tau phosphorylation by a single kinase can have isoform
specific outcomes. The mild nature of these changes, however, makes it unlikely that differential
effects of GSK-3β phosphorylation on the isoforms are causative in neurodegenerative disease.
Instead, the inherent differences in the isoform interactions themselves and local conditions in the
diseased cells are likely the major determinant of isoform involvement in various
neurodegenerative disorders.
Background
Tauopathies, such as Alzheimer's disease (AD), are charac-
terized by the abnormal aggregation of a hyperphosphor-
ylated microtubule associated protein, tau. The
aggregation and phosphorylation of tau correlates with
neurodegenerative changes in these diseases (reviewed in
[1]). It is therefore generally believed that aggregation and
phosphorylation changes are causative factors in the etiol-
ogy of tauopathies. One complicating factor to these
observations is that tau mRNA is alternatively spiced to
give rise to six protein isoforms. The isoforms are gener-
ated by splicing of exons 2, 3 and 10, which encodes for
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three microtubule binding repeats (3R) or four (4R) [2].
The levels of 3R and 4R tau do not differ between normal
and AD brains, but in both cases the levels of alternatively
spliced N-terminal exons differ. Isoforms with only exon
2 are the most abundant, followed by isoforms without N-
terminal exons and isoforms with both exons 2 and 3 are
the least abundant [3]. In other tauopathies, the ratio of
3R isoforms to 4R isoforms can be altered (reviewed in
[4]). For example, progressive supranuclear palsy (PSP)
can be accompanied by increases in 4R tau, while Pick's
Disease is often characterized by an increased amount of
3R isoforms (reviewed in [4]). These increases have been
explained in part by intronic mutations that promote or
hinder splicing of exon 10, but have no effect on the pro-
tein sequence (reviewed in [5]). The above observations
suggest that a shift in isoform expression may contribute
to neurodegenerative changes in tauopathies. However,
the individual contributions of tau isoforms to the neuro-
degenerative process are not well understood. One possi-
bility is that the inherent differences between isoforms are
sufficient to cause neurodegenerative changes when their
relative levels are altered.
Tau polymerization into filaments similar to those
observed in neurodegenerative diseases can be modeled
in vitro by the addition of inducer molecules such as ara-
chidonic acid (ARA) and heparin (reviewed in [6]) in a
complicated fashion [7]. It is currently unknown whether
different isoforms share ARA and heparin-induced polym-
erization profiles similar to 2N4R tau.
In addition to being abnormally polymerized, tau has
been shown to be hyperphosphorylated in AD pathology.
"Hyperphosphorylated" is a loosely defined term used to
describe abnormally or inappropriately phosphorylated
tau in AD. Although there is not a strict definition, some
properties of hyperphosphorylated tau include altered
electrophoretic mobility, conformational changes,
increased levels of phosphate incorporation, and site-spe-
cific inappropriate phosphorylation [8-10]. While it is not
known how hyperphosphorylated tau is generated, glyco-
gen synthase kinase-3β (GSK-3β) is widely believed to
play a role in this process (reviewed in [10]). In vitro,
GSK-3β phosphorylates tau at 14 sites that overlap with
AD-tau, as determined by mass spectrometry, and phos-
phorylation site-specific antibodies [11-14]. In vivo, treat-
ment of transgenic mouse models of tau-induced
neurodegeneration with lithium chloride, an inhibitor of
GSK-3β, reduces both tau phosphorylation and resulting
tau pathology [15,16]. Phosphorylation of 2N4R tau in
vivo by GSK-3β has reduced affinity for microtubules [17]
and phosphorylation of 0N3R tau in vitro by GSK-3β
shows mild changes in affinity of tau for microtubules
[18]. Recombinant tau phosphorylated by GSK-3β, upon
polymerization with an inducer, forms structures that
resemble neurofibrillary tangles in vitro [13,19]. How-
ever, it is not known how GSK-3β phosphorylation affects
the other tau isoforms, and given their differences in pri-
mary structure, it is possible that phosphorylation may
have differential impacts on their function. We have there-
fore characterized the polymerization and microtubule
binding properties for each isoform, and the effect that
phosphorylation by GSK-3β has on these properties.
We have found that there are fundamental differences in
the functions of 3R and 4R isoforms. These differences are
largely determined by the presence or absence of exon 10,
with some contributions from exons 2 and 3. Phosphor-
ylation by GSK-3β modulates the function of tau, but only
mildly. The data suggest that phosphorylation alters all
isoforms to approximately the same degree. These results
suggest that the inherent properties of the isoforms are
primarily responsible for their variable involvement in
disease pathology, rather than the differential effects
brought about by GSK-3β phosphorylation.
Results
Tau isoforms
The tau transcript is alternatively spliced in humans to
form six isoforms. These isoforms (0N3R, 0N4R, 1N3R,
1N4R, 2N3R, 2N4R) are classified by the presence or
absence of N-terminal exons 2, 3, and C-terminal exon 10
(containing microtubule binding repeat 2) (Figure 1a).
We expressed and purified each recombinant isoform
from E. coli (Figure 1b). The isoform identity was con-
firmed by molecular weight determination on coomassie
stained-sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) as compared to expected values
in the literature [9,20].
Isoform difference in arachidonic acid induced 
polymerization
Because the primary sequences of the tau isoforms are dif-
ferent, the various combinations of exons could influence
their interactions with inducer molecules or cause confor-
mational changes affecting tau-tau interactions during the
polymerization process. The polymerization characteris-
tics of each isoform was determined by incubating 2 μM
protein with a range of ARA concentrations (0–150 μM)
and monitoring the extent of polymerization with right
angle laser light scattering (LLS, Figure 2a) and thioflavine
S fluorescence (ThS, Figure 2b). We determined that
above 100 μM ARA, the results were highly variable and
not easily reproducible (data not shown). This is consist-
ent with previously published results showing high varia-
bility at the inhibitory ratio of inducer to 2N4R tau [7].
The isoforms followed the same general trend of increas-
ing amounts of polymerization with increasing inducer
concentrations. 4R tau isoforms (containing exon 10)Page 2 of 12
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2a & 2b), indicating that the additional microtubule bind-
ing repeat enhances tau polymerization.
The resulting filaments from the polymerization reactions
above were viewed by transmission electron microscopy
(TEM, Figure 2c–h). At equivalent ARA concentrations (75
μM), the greatest amount of filament formation was
observed with the 1N4R and 2N4R isoforms (Figure
2g,h). Fewer filaments were observed for 1N3R and 2N3R
(Figure 2d,e). Isoforms lacking both N-terminal exons
(0N3R and 0N4R, Figure 2c, f) tended to form very small
filaments (< 50 nm), as has been described previously
[20], but large aggregates of longer filaments were also
observed, albeit infrequently (Additional file 1). We, and
others, have found that while aggregates of tau polymer
can be detected by LLS and ThS fluorescence, these aggre-
gates may not be uniformly distributed on a TEM grid,
resulting in the user not being able to see these aggregates
unless they scan the entire grid.
Isoform differences in heparin induced polymerization
Because it is known that some isoforms do not polymerize
equally in the presence of heparin [21], the polymeriza-
tion characteristics for all six isoforms were determined
under conditions of low ionic strength [22,23]. The iso-
forms (2 μM) were incubated in the presence of varying
concentrations (0–0.024 mg/ml) of heparin and polymer-
ization was measured by LLS (Figure 3a) and ThS fluores-
cence (Figure 3b). Polymerization was detected by both
methods for the 4R isoforms, and the dose-response curve
was biphasic, indicating an optimal inducer concentra-
tion for polymerization. 2N4R required a lower concen-
tration of heparin for optimal polymerization than 0N4R
and 1N4R. Under these heparin induction conditions, the
3R isoforms failed to polymerize to detectable levels
above background (Figure 3a and 3b). 4R isoforms (Fig-
ure 3f–h) were induced to form long filaments, but 3R iso-
forms (Figure 3c–e) did not polymerize into any
observable filaments by TEM.
Tau isoforms are phosphorylated by GSK-3β
All six tau isoforms are abnormally hyperphosphorylated
in neurofibrillary tangles found in AD pathology. How-
ever the functional consequences of this phosphorylation
are unknown. Previous studies have found that tau phos-
phorylation, in general, reduces its binding to microtu-
bules [24]. Likewise, ARA induced filaments of GSK-3β
phosphorylated 2N4R tau coalesce into "neurofibrillary
tangle-like" structures [13,19]. To determine whether
GSK-3β exerted similar effects on other tau isoforms, we
examined the effects of GSK-3β phosphorylation by meas-
uring the extent of phosphorylation, microtubule binding
and ARA induced polymerization.
GSK-3β phosphorylation of 2N4R tau results in an
upward shift in mobility on SDS-PAGE gels [19]. The
effects of GSK-3β phosphorylation on the electrophoretic
mobility of the other isoforms was examined by visualiz-
ing phosphorylation reactions of each isoform by SDS-
PAGE (Figure 4a). All phosphorylated isoforms had an
upward shift in electrophoretic mobility compared to its
non-phosphorylated standard (Figure 4a). The quantity of
the shifted tau band was unequal for the different iso-
forms, despite equivalent conditions for phosphorylation.
One potential explanation for the differences in quantity
could be that the degree of phosphate incorporation is not
equal for all isoforms. Therefore, the levels of phosphor-
ylation by GSK-3β were determined directly for each iso-
form by using γ-32P ATP. An average of approximately 1
mole phosphate was incorporated per mole of tau for
each isoform (Figure 4b). Only 0N3R showed lower phos-
phate incorporation, but due to the variability in the reac-
tions, this difference did not reach statistically significant
levels. Therefore, the difference in electrophoretic mobil-
ity between phosphorylated and non-phosphorylated tau,
Differences between tau isoformsFigu  1
Differences between tau isoforms. (A) The six tau iso-
forms differ by the presence or absence of N-terminal exons 
2 and 3 and the presence or absence of the C-terminal exon 
10, which encodes microtubule binding repeat 2. Labels on 
the left indicate the isoform name, while labels on the right 
indicate the number of amino acids present in each corre-
sponding isoform. (B) Each lane is labeled with the name of 
the isoform analyzed. Each isoform migrates a distinct dis-
tance on a Coomassie stained 10% SDS-polyacrylamide gel.Page 3 of 12
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poration, but rather could be due to similar levels of phos-
phorylation resulting in different levels of SDS-resistant
conformational changes in the isoforms. Alternatively, the
difference in the quantity could be a result of experimen-
tal variability of phosphorylation by GSK-3β.
Microtubule binding of tau isoforms changes with 
phosphorylation by GSK-3β
Tau is a microtubule-associated protein that, when phos-
phorylated at specific sites in the microtubule binding
regions, such as at site S262 by p110MARK (microtubule
affinity regulating kinase), promotes strong disassociation
ARA induction of tau isoform polymerizationFigure 2
ARA induction of tau isoform polymerization. 2 μM tau isoforms were incubated with various ARA concentrations (0 
μM to 100 μM) for 18 hrs. Polymerization was measured by (A) LLS or (B) ThS fluorescence. Symbols correspond as follows: 
(open square) 0N3R, (closed square) 0N4R, (open triangle) 1N3R, (closed triangle) 1N4R, (open circle) 2N3R, (closed circle) 
2N4R, and (closed diamond) assembly incompetent protein (AIP (I277, 308P)). Data is in arbitrary units and represents an 
average of 3 trials ± SEM. After 18 hours, ARA induced polymerization reactions were visualized by TEM at 20,000x magnifica-
tion. Images are as follows: (C) 0N3R, (D) 1N3R, (E) 2N3R, (F) 0N4R, (G) 1N4R, and (H) 2N4R. Each isoform image is repre-
sentative of polymerized material at 75 μM ARA. Scale bars represent 1 μm.Page 4 of 12
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Heparin induction of tau isoform polymerizationFigu e 3
Heparin induction of tau isoform polymerization. 2 μM tau isoforms were mixed with various heparin concentrations 
(0 mg/ml to 0.024 mg/ml) and incubated 18 hrs. Polymerization was measured by (A) LLS or (B) ThS fluorescence. Symbols 
correspond as follows: (open square) 0N3R, (closed square) 0N4R, (open triangle) 1N3R, (closed triangle) 1N4R, (open circle) 
2N3R, (closed circle) 2N4R. Data is in arbitrary units and represents an average of 3 trials ± SEM except for 2N4R with 0.006 
and 0.018 mg/ml heparin, 1N4R with 0.024 mg/ml heparin, and 0N4R with 0.018 mg/ml heparin which were 2 trials. After 18 
hours, heparin induced polymerization reactions were visualized by TEM at 20,000× magnification. Images are as follows: (C) 
0N3R, (D) 1N3R, (E) 2N3R, (F) 0N4R, (G) 1N4R, and (H) 2N4R. Each isoform image is representative of polymerized material 
at 0.006 mg/ml heparin. Scale bars represent 1 μm.
Molecular Neurodegeneration 2009, 4:18 http://www.molecularneurodegeneration.com/content/4/1/18(~10×) from microtubules [25], while phosphorylation
outside of the microtubule binding regions (such as by
GSK-3β in the proline rich region) has weaker effects on
microtubule binding [26]. We therefore determined the
effects of phosphorylation by GSK-3β on the microtubule
binding affinities of each isoform, using unphosphor-
ylated protein as a control (Figure 5a–f). Unphosphor-
ylated 4R isoforms bound more tightly than the
unphosphorylated 3R isoforms (Figure 5g), which is con-
sistent with previously published results [27]. Upon phos-
phorylation, the largest decrease in microtubule affinities
occurred in 1N isoforms (~3×) (Figure 5g), indicating
GSK-3β phosphorylates 1N isoforms at sites that mildly
influence microtubule binding. The average Kd of phos-
phorylated 0N3R, 0N4R, and 2N4R isoforms was higher
than the corresponding unphosphorylated Kd, however,
these changes did not reach statistically significant levels
(Figure 5g). 2N3R showed an increase in affinity for
microtubules upon GSK-3β phosphorylation. These data
indicate that phosphorylation by GSK-3β has mild effects
on the microtubule binding of tau isoforms, which is con-
sistent with phosphorylation at the proline rich region or
other regions only mildly involved with microtubule
binding.
Phosphorylation of tau isoforms changes filament 
polymerization levels
To determine how phosphorylation affects polymeriza-
tion with ARA, all six isoforms were phosphorylated prior
to the induction of polymerization. Heparin was not used
because it failed to induce polymerization in non-phos-
GSK-3β phosphorylation of tau isoforms visualized by changes in gel m bi ity and phosphate incorporationFigur  4
GSK-3β phosphorylation of tau isoforms visualized by 
changes in gel mobility and phosphate incorporation. 
(A) The migration of GSK-3β phosphorylated tau isoforms 
(p) was compared to unphosphorylated isoforms (up) by 
Coomassie-stained SDS-PAGE. The isoforms are labeled 
above their respective lanes. 2N4R was analyzed on a sepa-
rate gel and then aligned by its relative migration to molecu-
lar weight standards. (B) γ-32P ATP was added to the 
phosphorylation reaction overnight and moles of phosphate 
per mole of tau was calculated by averaging 4 trials ± SEM. 
Each isoform in (B) is individually labeled underneath its 
respective value.
Changes in microtubule binding of tau isoforms when phos-phorylated with GSK-3βFigur  5
Changes in microtubule binding of tau isoforms when 
phosphorylated with GSK-3β. Microtubule binding reac-
tions were performed at varying concentrations of tau (0 μM 
to 10 μM) and bound vs. free tau (in μM) for both unphos-
phorylated (black circle) and phosphorylated (red circle) was 
plotted (A-F). Three separate trials are plotted together to 
demonstrate the variability in the reactions. The data were fit 
to a nonlinear single site binding equation for unphosphor-
ylated (black solid line) and phosphorylated (red solid line) 
tau isoforms (A-F). The 95% confidence intervals of the fits 
are drawn as dashed lines. Outliers existed for phosphor-
ylated samples, are shown as red open boxes, and were 
excluded from calculations. (G) The dissociation constant 
(Kd) (in μM) was determined for unphosphorylated (white 
bars) and phosphorylated (red bars) isoforms by Kd = the 
concentration of tau required to reach 1/2 Bmax. Data repre-
sents the average of 3 trials ± SEM.Page 6 of 12
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polymerization at 2 μM tau and 75 μM ARA was measured
by LLS and ThS fluorescence (Figure 6). Non-phosphor-
ylated and phosphorylated assembly incompetent tau
(AIP, I277/308P) was used to correct for background scat-
tering as previously described [28]. 2N3R (Figure 6a) and
1N3R (Figure 6c) had relatively unchanged ThS values,
but 2N3R had decreased LLS upon phosphorylation,
while 1N3R had increased LLS. The phosphorylated 2N4R
and 1N4R isoforms polymerized less than their unphos-
phorylated counterparts as measured by both LLS and
ThS. Phosphorylated 0N3R had increases in both LLS and
ThS, while 0N4R had no change in LLS, and decreased
ThS. The data indicate that phosphorylation does not
influence the polymerization of isoforms equally, but
these changes are mild in comparison to differences
between unphosphorylated isoforms.
Phosphorylation of tau isoforms changes filament 
morphology
Because LLS readings can be influenced by the size and
length of the particles [29] and it is not clear to which
molecular species ThS binds [30-32], samples of phos-
phorylated tau isoform filaments were viewed by TEM to
determine whether phosphorylation induces significant
changes in filament morphology, as has been observed
with 2N4R tau [13,19]. Representative micrographs of
phosphorylated samples polymerized in the presence of
75 μM ARA indicate distinct morphological changes from
unphosphorylated tau isoforms (Compare Figure 7 and
Figure 2). Phosphorylated 0N3R and 0N4R (Figure 7a, b)
isoforms had increases in the relative length and number
of filaments formed as compared to non-phosphorylated
(Figure 2c, f). Filaments formed from phosphorylated
1N3R and 1N4R (Figure 7c, d) isoforms also appeared to
be relatively more numerous, and longer than non-phos-
phorylated (Figure 2d, g), although these changes were
less dramatic than for the 0N isoforms. Phosphorylated
Effect of phosphorylation on tau isoform polymerizationFigure 6
Effect of phosphorylation on tau isoform polymeriza-
tion. Each isoform (A) 2N3R, (B) 2N4R, (C) 1N3R, (D) 
1N4R, (E) 0N3R, and (F) 0N4R was polymerized with 75 μM 
ARA after phosphorylation by GSK-3β (+p) or without phos-
phorylation (-p). Reactions were measured by LLS (black 
bars and left y-axis) and ThS fluorescence (open bars and 
right y-axis). All LLS data is background subtracted with AIP 
for -p and AIPp for +p values respectively. Data is an average 
of 3 trials ± SEM.
TEM analysis of ARA induction of GSK-3β phosphorylated tau isoformFigure 7
TEM analysis of ARA induction of GSK-3β phosphor-
ylated tau isoforms. Images are as follows: (A) 0N3R, (B) 
0N4R, (C) 1N3R, (D) 1N4R, (E) 2N3R, and (F) 2N4R. Images 
were recorded at a magnification of 20,000× (A-F) and are 
representative of polymerized material from 75 μM ARA 
induced-reactions presented in Figure 6. Scale bars represent 
1 μm.Page 7 of 12
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unchanged in the length and number of filaments (Figure
3e, h). Filaments from phosphorylated 0N3R, 1N4R, and
2N4R, had an increased tendency to cluster in close asso-
ciation to form "tangle-like" structures, similar to those
seen previously with phosphorylated 2N4R induced with
lower (25 μM) ARA concentrations [13,19]. It is apparent
that isoform and inducer concentration, as well as phos-
phorylation, affect filament interactions promoting "tan-
gle-like" structures.
Discussion
Many studies aimed at understanding the normal and
abnormal functions of the microtubule-associated protein
tau have focused on only one or two of its isoforms. How-
ever, all six isoforms of tau differ in their primary structure
and therefore can potentially differ in their functions. In
fact it has been shown that significant differences exist
between the microtubule binding and microtubule stabi-
lizing capacities of isoforms with three microtubule bind-
ing repeats and those with four microtubule binding
repeats [27,33]. It has also been demonstrated that there
are substantial differences between the self-polymeriza-
tion characteristics of three repeat isoforms and four
repeat isoforms [20,21] and between isoforms with differ-
ent numbers of N-terminal exons [20]. We have recently
demonstrated that the phosphorylation of the 2N4R iso-
form of tau by GSK-3β causes arachidonic acid induced
filaments to coalesce into larger structures similar to those
purified from Alzheimer's disease [13,19]. Due to the
potential differences between the characteristic functions
of tau isoforms, we investigated the effects of GSK-3β
phosphorylation on all six isoforms of tau.
As a necessary first step for this study, we established base-
line parameters for the self-polymerization of non-phos-
phorylated tau isoforms. This step was necessary because
it is clear the type of inducer used and the conditions for
polymerization have a large influence on the degree of
polymerization of tau isoforms [7,21-23]. Using arachi-
donic acid as an inducer for polymerization, we found
several significant differences between the isoforms. First,
four repeat isoforms polymerized to a greater extent than
three repeat isoforms. Secondly, removal of the two N-ter-
minal exons (exons 2 and 3) increased the concentration
of inducer required for maximal polymerization. Lastly,
the presence of exon 2 is sufficient to reduce the levels of
inducer required for maximal polymerization because the
addition of exon 3 to exon 2 containing isoforms does not
further reduce inducer concentrations needed for maxi-
mal polymerization.
Similar results were obtained for the heparin induction of
tau isoform polymerization. Four repeat isoforms polym-
erized in the presence of heparin while the amount of
three repeat isoform polymerization was greatly reduced
to undetectable levels. The N-terminal exons also influ-
enced the concentrations of inducer required to reach
maximal polymerization. The 2N4R isoform required less
heparin inducer for maximal polymerization than 1N4R
and 0N4R. The observation that three repeat isoforms
essentially failed to polymerize in the presence of heparin
was somewhat surprising because it has been shown that
the heparin induced polymerization of 0N3R tau is actu-
ally enhanced as compared to 2N4R tau [21]. It should be
noted that the aforementioned heparin polymerization
studies were incubated at higher protein and inducer con-
centrations in solutions with greater ionic strength and for
longer time periods than the current study. Our condi-
tions for polymerization are based on previously pub-
lished conditions of low ionic strength, protein
concentration and inducer concentration that result in
efficient tau polymerization reaching apparent steady
state in 24–48 hours [22,23]. These results indicate that
the local environment has a large impact on how individ-
ual tau isoforms self-polymerize, which could have an
impact on isoform specific regulation of tau in the cell.
Our results and those of others strongly suggest that most
isoforms of tau have distinct polymerization characteris-
tics. The local environment is a major determinant of the
amount of polymerization observed, and the isoforms do
not respond equally to changes in environment. GSK-3β
has been shown to phosphorylate tau in transgenic mice
and cause neurodegeneration [34], which can be abol-
ished with lithium treatment to inhibit GSK-3β [15].
Based on these observations, we examined GSK-3β phos-
phorylation of tau isoforms.
The levels of GSK-3β phosphorylation of the isoforms
were similar at an average of approximately 1 mole of
phosphate per mole of tau, although there was a large
degree of variability in the amount of phosphate incorpo-
ration in repeated experiments. On average, the 0N3R iso-
form was phosphorylated to a lesser degree than the other
isoforms, but not at statistically significant levels. Based
on previous results, it is likely that phosphorylation
occurs at more than one site. 2N4R tau phosphorylated by
GSK-3β in vitro resulted in approximately 2–4 moles of
phosphate per mole of tau distributed among eleven sites
[12,13]. Phosphorylation by GSK-3β resulted in upward
shifts in gel mobility assays, indicating that phosphoryla-
tion generates an SDS-resistant conformational change in
each of the isoforms. Based on these data, it would be dif-
ficult to conclude that GSK-3β preferentially phosphor-
ylates any particular isoform in vitro.
Although the level of GSK-3β phosphorylation was
approximately equal, there were differences in the effects
on isoform functions. As expected, four repeat tau iso-Page 8 of 12
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repeat isoforms. Phosphorylation by GSK-3β decreased
the average Kd of 0N3R, 0N4R and 2N4R, but not at statis-
tically significant levels due to the variability in the data.
The 2N3R isoform bound more tightly to microtubules
upon phosphorylation, which is not unprecedented for
the effects of phosphorylation on tau-microtubule inter-
actions [35]. The largest differences were observed for the
1N isoforms. Both 1N3R and 1N4R had approximately 3-
fold reductions in microtubule binding following GSK-3β
phosphorylation. While phosphorylation with GSK-3β
affects microtubule binding differently for each isoform,
these effects are small as compared to kinases (such as
p110MARK at S262) which cause a complete loss in micro-
tubule binding of tau [25].
The effect of GSK-3β phosphorylation on the ARA induc-
tion of tau polymerization also differed between iso-
forms. In general, phosphorylation decreased the amount
of detectable polymerization by ThS fluorescence for the
4R isoforms and had little effect on the polymerization of
3R isoforms. It is difficult to assess the amount of polym-
erization detected by LLS since the phosphorylation proc-
ess seemed to increase the tendency of several isoforms to
cluster into larger structures. These larger structures can
potentially result in aberrant scattering [28,29,36,37]. The
largest changes observed due to phosphorylation occurred
with filament morphology as viewed by TEM. When com-
pared to the unphosphorylated state, each isoform tended
to increase in length and some showed increased affinities
between polymers. However, the physiological relevance
of such changes in morphology is unknown.
GSK-3β phosphorylation influences each of the tau iso-
forms differently, although these changes appear to be
small in comparison to the inherent differences in the
non-phosphorylated proteins. For example, GSK-3β phos-
phorylation reduces the ARA induced polymerization of
the 4R isoforms, but the phosphorylated versions still
polymerize to a greater degree than the non-phosphor-
ylated 3R isoforms. GSK-3β phosphorylation of tau iso-
forms does alter their microtubule binding in a variable
manner, but these changes are small, with the greatest
effect on binding being an approximate 3-fold reduction
in binding.
Conclusion
In conclusion, GSK-3β phosphorylation has different
impacts on the functions of the six isoforms of tau. How-
ever, the effect of GSK-3β phosphorylation on tau function
appears to be less significant than the pre-existing differ-
ences in isoform function based on their primary structure.
These inherent differences in the isoforms seem to react dif-
ferently to the local environment which appears to be the
major determinant of the amount of polymerization. How-
ever, GSK-3β was the only kinase examined in these studies,
and there are numerous other kinases that are known to be
involved in phosphorylating tau in vivo. Since we are only
looking at unprimed sites, it is plausible that priming with
other kinases before GSK-3β phosphorylation may have
more profound effects on isoform function. This work is
therefore a vital first step in understanding the effects of
phosphorylation and hyperphosphorylation on the func-
tional biochemical properties of tau isoforms.
Methods
Chemicals and Reagents
Arachidonic acid was obtained from Cayman Chemicals
(Ann Arbor, MI), IPTG from Calbiochem (EMD Bio-
sciences, La Jolla, CA), SDS-PAGE protein marker from
Invitrogen (Gaithersburg, MD), thioflavine S and GSK-3β
from Sigma (St. Louis, MO), urea from Bio-Rad (Hercules,
CA), and uranyl acetate and formvar carbon coated grids
from Electron Microscopy Sciences (Hatfield, PA). Tubu-
lin and tubulin buffer components were from Cytoskele-
ton, Inc (Denver, CO). Constructs for the histidine tagged
tau isoforms (0N3R, 0N4R, 1N3R, 1N4R, 2N3R and
2N4R) were a kind gift of Lester Binder. The construct for
histidine tagged assembly incompetent tau (AIP (I277/
308P)) was a kind gift from Jeff Kuret. Isoforms were
expressed in E. coli and purified by nickel affinity chroma-
tography using Chelating Sepharose Fast Flow (GE
Healthcare Bio-Sciences, Corp, Piscataway, NJ) and size
exclusion chromatography as previously described for
2N4R tau [19]. Protein concentration was determined by
a commercial BCA assay (Pierce Chemical, Rockford, IL).
Tau polymerization with ARA and heparin
Arachidonic acid (ARA) induction: Individual tau iso-
forms at a final protein concentration of 2 μM were incu-
bated in polymerization buffer containing 10 mM Hepes
pH 7.64, 100 mM NaCl, 0.1 mM EDTA and 5 mM DTT in
the presence of varying concentrations of ARA (0 μM–150
μM, concentration of ethanol carrier was kept constant at
3.75% for all reactions) for 18 hours at 23°C. Reaction
volumes were 200 μL.
Heparin induction: Individual tau isoforms at a final pro-
tein concentration of 2 μM were incubated in polymeriza-
tion buffer containing 30 mM Hepes pH 7.64, 20 mM
NaCl and 5 mM DTT induction reactions (200 μL total) in
the presence of varying concentrations of heparin (0 mg/
ml–0.024 mg/ml) for 18 hours at 37°C. Data for one of
the three trials for 2N4R with 0.006 and 0.018 mg/ml
heparin, 1N4R with 0.024 mg/ml heparin, and 0N4R with
0.018 mg/ml heparin were found to be inconsistent
(greater than 33% different) from the other data and were
not included in the graphs.
Right Angle Laser Light Scattering
Tau polymerization reactions were incubated for 18
hours, and assayed by right angle laser light scattering asPage 9 of 12
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5 mW solid state 475 nm laser (B & W Tek, Inc., Newark,
DE) and the resulting images of scattered light perpendic-
ular to the incoming light were captured with a digital
camera (Sony XC-ST270), imported into Adobe Pho-
toshop and using the histogram function of the program
assigned a value [7].
Thioflavine S Fluorescence
Polymerization reactions were incubated for 18 hours,
and assayed by ThS fluorescence as described in [7].
Briefly, ThS was added to reactions at a final concentration
of 20 μM and fluorescence was measured at λex of 440 nm
and λem of 520 nm [7].
Transmission Electron Microscopy
Polymerization reactions were prepared for TEM by meth-
ods previously described [7]. Briefly, reactions were
diluted 1:5, fixed with 2% glutaraldehyde, placed on
formvar-carbon coated grids (Electron Microscopy Sci-
ences Hatfield, PA), and stained with 2% uranyl acetate
(Electron Microscopy Sciences Hatfield, PA) [7]. Prepared
grids were viewed with a JEOL 1200 EXII electron micro-
scope, and images were captured with the MegaViewII
imaging system (Soft Imaging System, GmbH Münster,
Germany).
GSK-3β phosphorylation of tau isoforms
GSK-3β (Sigma Aldrich, St. Louis, MO) phosphorylation
reactions (25 μL) of each tau isoform contained 16.66 μM
tau, 0.018 U GSK-3β per pmol of tau in buffer containing
40 mM HEPES, pH 7.64, 5 mM EGTA, 3 mM MgCl2, and
2 mM ATP. One unit is defined as the amount of GSK-3
required to catalyze the transfer of 1 pmol phosphate to
tau in 1 min at 30°C in a reaction volume of 25 μl. Reac-
tions were incubated for 20 hours at 30°C [19]. The
degree of phosphorylation was determined by examining
the reaction products by 10% SDS-PAGE.
ARA polymerization of GSK-3β phosphorylated tau 
isoforms
25 μL phosphorylation reactions of the individual iso-
forms (see above) were diluted into ARA containing
polymerization reactions, as previously described in [19].
γ-32P ATP Phosphate incorporation
Tau protein was phosphorylated as detailed in [19].
Briefly, tau was phosphorylated with 2 μM ATP plus 3.125
μCi [γ-32P] labeled ATP (Perkin-Elmer, Boston, MA). Sam-
ples were filtered and washed to remove unincorporated
γ-32P, then counted in a liquid scintillation counter (Pack-
ard 1600TR) [19].
Unphosphorylated Microtubule Binding
Microtubule binding assays were performed using the
commercially available Microtubule Binding Protein
Assay Kit (Cytoskeleton, Inc., Denver, CO) using the man-
ufacturer's protocol. Varying concentrations of tau (0 μM–
10 μM) were mixed with a constant concentration of pacl-
itaxel stabilized microtubules at a final concentration of
1.6 μM tubulin dimers and 20 μM paclitaxel in a 50 μL
reaction with the general tubulin buffer supplied with the
kit (80 mM PIPES, pH 7.0, 2 mM MgCl2, 0.5 mM EGTA).
Samples were incubated at room temperature for 30 min-
utes, and centrifuged at 23°C in 7 × 20 mm polycarbonate
Beckman centrifuge tubes in a Beckman TLA 100 rotor at
100,000 × g for 5 minutes to sediment the microtubules
and tau bound to microtubules. The pellets were resus-
pended in 1 × SDS sample buffer (0.0625 M Tris, 2% SDS,
10% glycerol, 5% β-mercaptoethanol) and tau bound to
microtubules were separated from the pelleted tubulin by
electrophoresis. The SDS-polyacrylamide gels were
scanned with a Hewlett Packard Scanjet 7400 C and the
density of the tau contained in the pellet (bound tau) was
determined using Adobe Photoshop and a tau standard
curve on the same SDS-polyacrylamide gel. Isoforms
0N3R, 0N4R, 1N3R, and tubulin have similar electro-
phoretic mobility. In order to distinguish tau from tubu-
lin bands, the protein were transferred to PVDF by
standard western blot techniques and probed with tau
46.1 primary antibody (gift from Lester I. Binder) and
goat anti-mouse horseradish peroxidase conjugated sec-
ondary (Pierce). Amersham ECL Plus Western Blotting
Detection System was used to detect the secondary anti-
body (GE Healthcare). The PVDF membrane was visual-
ized using the Kodak Image Station 4000R (Eastman
Kodak Co, Molecular Imaging Systems, Rochester, NY).
Band intensities were determined by the histogram func-
tion of Adobe Photoshop. The amount of free tau left in
solution was determined by subtracting the amount of tau
in the bound fraction from the total amount of tau added
to the reaction and normalized to the band intensity of
tubulin. The concentrations of tau free in solution versus
bound tau were plotted in GraphPad Prism 4 and fit to a
noncooperative single-site binding equation: Free = (Bmax
* Bound)/(kd + Bound). Binding reactions were per-
formed in triplicate for all tau isoforms.
Phosphorylated microtubule binding
Individual tau isoform phosphorylation reactions (92
μL), containing 18.11 μM final concentration of tau,
0.018 U GSK-3β per pmol of tau in buffer containing 40
mM HEPES, pH 7.64, 5 mM EGTA, 3 mM MgCl2, and 2
mM ATP were incubated for 20 hours at 30°C. Microtu-
bule binding reactions were carried out as described above
and separated by SDS-polyacrylamide gel electrophoresis.
0N3R, 0N4R, and 1N3R were transferred to PVDF by
standard western blotting techniques as described above,
and PVDF blots were treated with shrimp alkaline phos-
phatase (Roche) before blocking, to remove the phos-
phate groups that interfere with tau 46.1 antibody
binding. Images of gels and blots were collected and proc-Page 10 of 12
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large concentration of tubulin we were unable to normal-
ize the data to the corresponding band. Due to variable
data, 5 outliers were excluded from calculations based
upon being more than twice as different as the corre-
sponding trials. These points are 0N4Rp trial 3 1 μM and
2 μM, 1N3Rp trial 1 8 μM and trial 2 10 μM, and 2N3Rp
trial 2 10 μM.
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